Evidence map›Paper›PMID 35313903›Full record

ArticleHarm reduction journal2022

The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study.

Brendan Lew, Claire Bodkin, Robin Lennox, Timothy O'Shea, Gillian Wiwcharuk, Suzanne Turner

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. COVID-19 isolation and recovery sites evaluation: Lessons learned for systems innovation.Canadian journal of public health = Revue canadienne de sante publique · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Perceived impacts of North Americas first de-medicalized safer supply program.Substance abuse treatment, prevention, and policy · 2025
    Article
  11. Using illicit drugs alone in Vancouver, Canada: a gender-based analysis.Substance abuse treatment, prevention, and policy · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Operating an overdose prevention site within a temporary emergency shelter during the COVID-19 pandemic.Canadian journal of public health = Revue canadienne de sante publique · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Brendan LewDepartment of Family Medicine, McMaster University, 100 Main St West, Hamilton, ON, L8P 1H6, Canada.
Claire BodkinDepartment of Family Medicine, McMaster University, 100 Main St West, Hamilton, ON, L8P 1H6, Canada.
Robin LennoxDepartment of Family Medicine, McMaster University, 100 Main St West, Hamilton, ON, L8P 1H6, Canada.
Timothy O'SheaDepartment of Medicine, McMaster University, 1200 Main St West, Hamilton, ON, L8N 3Z5, Canada.
Gillian WiwcharukDepartment of Family Medicine, McMaster University, 100 Main St West, Hamilton, ON, L8P 1H6, Canada.
Suzanne TurnerDepartment of Family Medicine, McMaster University, 100 Main St West, Hamilton, ON, L8P 1H6, Canada. suzanne.turner@utoronto.ca.
McMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOpioid-related harms, including fatal and non-fatal overdoses, rose dramatically during the COVID-19 pandemic and presented unique challenges during outbreaks in congregate settings such as shelters. People who are deprived of permanent housing have a high prevalence of substance use and substance use disorders, and need nimble, rapid, and portable harm reduction interventions to address the harms of criminalized substance use in an evidence-based manner. CASE STUDY: In February 2021, a COVID-19 outbreak was declared at an emergency men's shelter in Hamilton, Ontario, Canada. Building on pre-existing relationships, community and hospital-based addictions medicine providers and a local harm reduction group collaborated to establish a shelter-based opioid agonist treatment and safer supply program, and a volunteer run safer drug use space that also distributed harm reduction supplies. In the 4 weeks preceding the program, the rate of non-fatal overdoses was 0.93 per 100 nights of shelter bed occupancy. During the 26 days of program operation, there were no overdoses in the safer use space and the rate of non-fatal overdoses in the shelter was 0.17 per 100 nights of shelter bed occupancy. The odds ratio of non-fatal overdose pre-intervention to during intervention was 5.5 (95% CI 1.63-18.55, p = 0.0059). We were not able to evaluate the impact of providing harm reduction supplies and did not evaluate the impact of the program on facilitating adherence to public health isolation and quarantine orders. The program ended as the outbreak waned, as per the direction from the shelter operator.

conclusionsThere was a significant reduction in the non-fatal overdose rate after the safer drug use and safer supply harm reduction program was introduced. Pre-existing relationships between shelter providers, harm reduction groups, and healthcare providers were critical to implementing the program. This is a promising approach to reducing harms from the criminalization of substance use in congregate settings, particularly in populations with a higher prevalence of substance use and substance use disorders.

Indexed as

COVID-19Disease OutbreaksEmergency ShelterHumansMaleOntarioPandemicsCase studyControlled substancesHomeless sheltersOverdoseSubstance use

Identifiers

PMID35313903
PMCPMC8935259
OpenAlexW4221124673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.